Stockreport

FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer

IMMUNOMEDICS  (IMMU) 
Last immunomedics earnings: 2/27 04:00 pm Check Earnings Report
PDF MORRIS PLAINS, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the [Read more]